Refractory Small Lymphocytic Lymphoma (DBCOND0029146)

Identifiers

Synonyms

Refractory small lymphocytic lymphoma

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Duvelisib	An inhibitor of phosphatidylinositol 3-kinase delta and gamma used to treat relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.	Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformtarget Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget
Lisocabtagene maraleucel	A CAR T-cell therapy for treatment resistant or more severe B-cell lymphomas.	B-lymphocyte antigen CD19target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04781855	Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation	Ibrutinib Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT05828589	A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies	No drug interventions	treatment	1	recruiting
NCT04892277	CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT04578600	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	Azacitidine Lenalidomide Obinutuzumab	treatment	1	active_not_recruiting
NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Hyaluronidase (human recombinant) Polatuzumab vedotin Rituximab Venetoclax	treatment	2	terminated
NCT04195633	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies	Cyclophosphamide Cyclosporine Filgrastim Fludarabine Mycophenolate mofetil Mycophenolic acid Treosulfan	treatment	2	recruiting
NCT02568553	Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma	Blinatumomab Lenalidomide Muromonab	treatment	1	active_not_recruiting
NCT01619761	NK Cells in Cord Blood Transplantation	Cyclophosphamide Fludarabine Lenalidomide Mechlorethamine Mycophenolate mofetil Natural Killer Cell Rituximab Tacrolimus	treatment	1	unknown_status
NCT03579888	CD19-Specific T Cells Post AlloSCT	Cyclophosphamide Fludarabine	treatment	1	terminated
NCT02160015	Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery	Ibrutinib Lenalidomide Rituximab	treatment	1	active_not_recruiting
NCT04169737	Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Acalabrutinib Obinutuzumab Tyrosine Venetoclax	treatment	2	recruiting
NCT01886859	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Ibrutinib Lenalidomide	treatment	1	completed
NCT02225275	Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Lenalidomide Obinutuzumab	treatment	2	terminated
NCT00723099	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT04995536	CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL	No drug interventions	treatment	1	withdrawn
NCT03639324	Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL	No drug interventions	treatment	1	withdrawn
NCT04941716	Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Acalabrutinib Tyrosine Venetoclax	treatment	2	recruiting
NCT00789776	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Natural Killer Cell Tacrolimus	treatment	1 / 2	completed
NCT04007029	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Cyclophosphamide Fludarabine Tocilizumab	treatment	1	recruiting
NCT01381692	Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	Bortezomib Bortezomib D-mannitol Dexamethasone Menthol Rituximab Sirolimus Temsirolimus	treatment	1 / 2	completed
NCT00005803	Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	Beta-D-Glucose Carmustine Cyclophosphamide Cyclosporine Cytarabine Etoposide Fludarabine Mechlorethamine Mycophenolate mofetil	treatment	1 / 2	completed
NCT06191887	B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT02756897	Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia	Ibrutinib Venetoclax	treatment	2	active_not_recruiting
NCT03045328	Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL	Ibrutinib Venetoclax	treatment	2	completed
NCT01865617	Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia	No drug interventions	treatment	1 / 2	completed
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	Abemaciclib Abiraterone Afatinib Albumin human Avobenzone Bevacizumab Bicalutamide Bortezomib Bortezomib D-mannitol Cabazitaxel Cabozantinib Capecitabine Carboplatin Celecoxib Cobimetinib Copanlisib Dabrafenib Dacomitinib Darolutamide Dasatinib Daunorubicin Doxorubicin Durvalumab Enasidenib Entrectinib Enzalutamide Erlotinib Everolimus Fluorouracil Idelalisib Imatinib Ipilimumab Lenvatinib Leucovorin Lorlatinib Losartan Neratinib Nivolumab Octinoxate Olaparib Oxaliplatin Paclitaxel Palbociclib Panobinostat Pembrolizumab Pertuzumab Ponatinib Regorafenib Ruxolitinib Sirolimus Sorafenib Sunitinib Trametinib Trastuzumab emtansine Tretinoin Vemurafenib Venetoclax Vismodegib Vorinostat	treatment	1	terminated
NCT03010358	Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	Entospletinib Obinutuzumab	treatment	1 / 2	completed
NCT01008462	Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	Beta-D-Glucose Carmustine Cyclophosphamide Cytarabine Etoposide Fludarabine Mechlorethamine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT02332980	Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	Ibrutinib Idelalisib Pembrolizumab	treatment	2	completed
NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT04230304	Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study	Daratumumab Ibrutinib	treatment	2	active_not_recruiting
NCT03961672	Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Duvelisib	treatment	2	active_not_recruiting
NCT03884972	Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor	Trabectedin Venetoclax	treatment	1	withdrawn
NCT03479268	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	Ibrutinib Pevonedistat	treatment	1	active_not_recruiting
NCT01995669	Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma	Lenalidomide Obinutuzumab	treatment	1 / 2	completed
NCT03003546	Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial	Paclitaxel Rituximab	treatment	1	completed
NCT02420912	Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation	Ibrutinib Nivolumab	treatment	2	completed
NCT02614508	Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	Buparlisib Ibrutinib Ofatumumab	treatment	1	terminated